Type II endometrial cancers constitute the minority of cases, but are typified by an aggressive clinical course with a distinct pattern of metastasis, older age at presentation, the absence of antecedent history of unopposed estrogen, and serous, clear cell or grade 3 endometrioid histology [7,8]; aneuploidy, mutations in p53, and Her2/Neu overexpression are common [9-12]. This evidence concerns the gene ERBB2 and endometrial cancer.